Genetic testing, including germline and somatic, is vital for prostate cancer prognosis and personalized treatment strategies. PARP inhibitors, targeting BRCA mutations, are a promising therapy for ...

The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.

Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later ...